From SARS-CoV-2 hematogenous spreading to endothelial dysfunction: clinical-histopathological study of cutaneous signs of COVID-19.


Journal

Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558

Informations de publication

Date de publication:
25 Feb 2021
Historique:
received: 27 07 2020
accepted: 09 02 2021
entrez: 26 2 2021
pubmed: 27 2 2021
medline: 4 3 2021
Statut: epublish

Résumé

To date, very few studies on clinical-histopathological correlations of cutaneous disorders associated with COVID-19 have been conducted. The Case 1 was a 90-year-old man, who tested positive for SARS-CoV-2 from a nasopharyngeal swab. Two days later, he was hospitalized and after eleven days transferred to Intensive Care Unit. A chest CT showed bilateral ground-glass opacities. Just that day, an erythematous maculo-papular rash appeared on trunk, shoulders and neck, becoming purpuric after few days. Histological evaluations revealed a chronic superficial dermatitis with purpuric aspects. The superficial and papillary dermis appeared edematous, with a perivascular lympho-granulocytic infiltrate and erythrocytic extravasation. At intraepithelial level, spongiosis and a granulocyte infiltrate were detected. Arterioles, capillaries and post-capillary venules showed endothelial swelling and appeared ectatic. The patient was treated with hydroxychloroquine, azithromycin, lopinavir-ritonavir and tocilizumab. Regrettably, due to severe lung impairment, he died. The Case 2 was a 85-year-old man, admitted to Intensive Care Unit, where he was intubated. He had tested positive for SARS-CoV-2 from a nasopharyngeal swab two days before. A chest RX showed bilateral atypical pneumonia. After seven days, a cutaneous reddening involving trunk, upper limbs, neck and face developed, configuring a sub-erythroderma. Histological evaluations displayed edema in the papillary and superficial reticular dermis, and a perivascular lymphocytic infiltrate in the superficial dermis. The patient was treated with hydroxychloroquine, azithromycin, lopinavir-ritonavir and tocilizumab. Sub-erythroderma as well as respiratory symptoms gradually improved until healing. The endothelial swelling detected in the Case 1 could be a morphological expression of SARS-CoV-2-induced endothelial dysfunction. We hypothesize that cutaneous damage could be initiated by endothelial dysfunction, caused by SARS-CoV-2 infection of endothelial cells or induced by immune system activation. The disruption of endothelial integrity could enhance microvascular permeability, extravasation of inflammatory cells and cytokines, with cutaneous injury. The Case 2 developed a sub-erythroderma associated with COVID-19, and a non-specific chronic dermatitis was detected at histological level. We speculate that a purpuric rash could represent the cutaneous sign of a more severe coagulopathy, as highlighted histologically by vascular abnormalities, while a sub-erythroderma could be expression of viral hematogenous spreading, inducing a non-specific chronic dermatitis.

Sections du résumé

BACKGROUND BACKGROUND
To date, very few studies on clinical-histopathological correlations of cutaneous disorders associated with COVID-19 have been conducted.
CASE PRESENTATION METHODS
The Case 1 was a 90-year-old man, who tested positive for SARS-CoV-2 from a nasopharyngeal swab. Two days later, he was hospitalized and after eleven days transferred to Intensive Care Unit. A chest CT showed bilateral ground-glass opacities. Just that day, an erythematous maculo-papular rash appeared on trunk, shoulders and neck, becoming purpuric after few days. Histological evaluations revealed a chronic superficial dermatitis with purpuric aspects. The superficial and papillary dermis appeared edematous, with a perivascular lympho-granulocytic infiltrate and erythrocytic extravasation. At intraepithelial level, spongiosis and a granulocyte infiltrate were detected. Arterioles, capillaries and post-capillary venules showed endothelial swelling and appeared ectatic. The patient was treated with hydroxychloroquine, azithromycin, lopinavir-ritonavir and tocilizumab. Regrettably, due to severe lung impairment, he died. The Case 2 was a 85-year-old man, admitted to Intensive Care Unit, where he was intubated. He had tested positive for SARS-CoV-2 from a nasopharyngeal swab two days before. A chest RX showed bilateral atypical pneumonia. After seven days, a cutaneous reddening involving trunk, upper limbs, neck and face developed, configuring a sub-erythroderma. Histological evaluations displayed edema in the papillary and superficial reticular dermis, and a perivascular lymphocytic infiltrate in the superficial dermis. The patient was treated with hydroxychloroquine, azithromycin, lopinavir-ritonavir and tocilizumab. Sub-erythroderma as well as respiratory symptoms gradually improved until healing.
CONCLUSIONS CONCLUSIONS
The endothelial swelling detected in the Case 1 could be a morphological expression of SARS-CoV-2-induced endothelial dysfunction. We hypothesize that cutaneous damage could be initiated by endothelial dysfunction, caused by SARS-CoV-2 infection of endothelial cells or induced by immune system activation. The disruption of endothelial integrity could enhance microvascular permeability, extravasation of inflammatory cells and cytokines, with cutaneous injury. The Case 2 developed a sub-erythroderma associated with COVID-19, and a non-specific chronic dermatitis was detected at histological level. We speculate that a purpuric rash could represent the cutaneous sign of a more severe coagulopathy, as highlighted histologically by vascular abnormalities, while a sub-erythroderma could be expression of viral hematogenous spreading, inducing a non-specific chronic dermatitis.

Identifiants

pubmed: 33632250
doi: 10.1186/s13000-021-01075-6
pii: 10.1186/s13000-021-01075-6
pmc: PMC7905980
doi:

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

16

Références

J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e457-e459
pubmed: 32386448
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e453-e454
pubmed: 32358895
Clin Exp Dermatol. 2020 Oct;45(7):892-895
pubmed: 32385858
J Dermatol Sci. 2020 May;98(2):141-143
pubmed: 32381428
Angiogenesis. 2020 Nov;23(4):611-620
pubmed: 32458111
JAMA Dermatol. 2020 Jul 1;156(7):820-822
pubmed: 32352487
J Am Acad Dermatol. 2020 Jun;82(6):e227
pubmed: 32278800

Auteurs

Angela Patrì (A)

Department of Clinical Medicine and Surgery, Section of Dermatology and Venereology, University of Naples Federico II, Via Pansini 5, Napoli, Italy. patriangela.ap@gmail.com.

Maria Vargas (M)

Department of Neurosciences, Intensive Care Unit, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Via Pansini 5, Napoli, Italy.

Pasquale Buonanno (P)

Department of Neurosciences, Intensive Care Unit, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Via Pansini 5, Napoli, Italy.

Maria Carmela Annunziata (MC)

Department of Clinical Medicine and Surgery, Section of Dermatology and Venereology, University of Naples Federico II, Via Pansini 5, Napoli, Italy.

Daniela Russo (D)

Department of Advanced Biomedical Sciences, Pathology Section, University of Naples Federico II, via Pansini 5, Naples, Italy. danielarusso83@yahoo.it.

Stefania Staibano (S)

Department of Advanced Biomedical Sciences, Pathology Section, University of Naples Federico II, via Pansini 5, Naples, Italy.

Giuseppe Servillo (G)

Department of Neurosciences, Intensive Care Unit, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Via Pansini 5, Napoli, Italy.

Gabriella Fabbrocini (G)

Department of Clinical Medicine and Surgery, Section of Dermatology and Venereology, University of Naples Federico II, Via Pansini 5, Napoli, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH